Ascending Dose Study of the Safety and Tolerability of Alirocumab (SAR236553/REGN727) in Japanese Healthy Volunteers

NCT01448317 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia

Interventions

DRUG: Alirocumab (Solution)
DRUG: Alirocumab (Lyophilized formulation)
DRUG: Placebo (Solution)
DRUG: Placebo (Lyophilized formulation)

Sponsor

Sanofi

Collaborators

[object Object]